stockrow
Friday 6 November 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
Lisata Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170,000.00, down 83.0% from fiscal 2024.
- Revenue
- −98.3%
- EPS
- +40.7%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
1.02
0.03
+3.03%
Follow LSTA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 0 | 15 | (83.0%) | 7 | 7 | 7 | +248.6% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 0.49 | +100.0 pt | ||||||
| EBT | (31) | (28) | (16) | (19) | (19) | (29) | (57) | (23) | (21) | (18) | (15) | (6.2%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,078.30) | (10,322.35) | 0.00 | (10,322.3) pt | ||||||
| Net income | (33) | 22 | (16) | (19) | (8) | (27) | (54) | (21) | (20) | (17) | (15) | (7.5%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | 0.00 | n/m | |||||
| Earnings | (74.81) | 38.38 | (25.04) | (28.19) | (7.95) | (7.50) | (10.47) | (2.58) | (2.40) | (1.91) | (1.64) | (33.5%) | ||||||
| Cash flow | (54.18) | (34.90) | (30.92) | (27.42) | (8.57) | (6.03) | (4.09) | (2.48) | (2.32) | (1.84) | (1.35) | (31.3%) | ||||||
| Capex | (2.52) | (0.23) | (0.21) | 0.00 | (0.02) | (0.02) | (0.05) | 0.00 | 0.00 | 0.00 | 0.00 | (52.3%) | ||||||
| Free cash flow | (56.70) | (35.12) | (31.13) | (27.42) | (8.59) | (6.05) | (4.14) | (2.48) | (2.32) | (1.84) | (1.35) | (31.7%) | ||||||
| Book value | 9.31 | 83.90 | 57.95 | 29.84 | 31.31 | 24.95 | 12.80 | 5.93 | 3.52 | 1.68 | 0.88 | (17.3%) | ||||||
| Shares, m | 0 | 1 | 1 | 1 | 1 | 4 | 5 | 8 | 8 | 9 | 9 | +39.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.93 | 1.06 | 0.61 | 1.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.85 | 1.11 | 1.16 | 1.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | (0.12) | 0.22 | 0.14 | 0.1 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.16 | (0.21) | (0.17) | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (24) | (21) | (20) | (19) | (9) | (22) | (21) | (20) | (19) | (16) | (12) | (4.3%) | |||||
| Capex | (1) | 0 | 0 | — | 0 | 0 | 0 | — | — | 0 | 0 | (33.5%) | ||||||
| Free cash flow | (25) | (21) | (20) | (19) | (9) | (22) | (21) | (20) | (19) | (16) | (12) | (4.8%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 3 | 52 | 38 | 20 | 32 | 92 | 65 | 47 | 29 | 15 | 8 | +17.4% | |||||
| Net debt | (1) | (60) | (43) | (25) | (35) | (95) | (69) | (51) | (31) | (16) | (10) | +32.5% | ||||||
| Shareholders’ equity | 4 | 50 | 37 | 21 | 32 | 92 | 66 | 48 | 29 | 15 | 8 | +15.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (58.99) | 39.32 | (29.95) | (53.98) | (25.81) | (41.30) | (63.78) | (32.63) | (44.56) | (62.89) | (80.81) | (3.9) pt | |||||
| ROIC | (658.43) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +658.4 pt | ||||||
| ROE | (238.80) | 84.71 | (36.89) | (66.75) | (30.87) | (44.21) | (68.50) | (36.49) | (51.77) | (75.53) | (101.66) | +163.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 209 | 22 | 25 | 27 | 24 | 27 | 27 | 25 | 26 | 21 | — | (22.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 26 Oct 2026
Lisata Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | |
| GDTC CytoMed Therapeutics Limited | $10.4M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| PTN Palatin Technologies, Inc. | $10.2M | 13.6× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $10.4M | — | — | −14.06% | — | −8.53% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 19 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.15m | 937.85k | 73.52 |
| 2024 | 1.69m | 1.68m | 117.79 |
| 2023 | 1.41m | 1.31m | 107.91 |
Ownership
Directors and executive officers, together
8.40%
Erkki Ruoslahti, M.D., Ph.D
10.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement